2H51 Stock Chart & Stats
€1.06
-€0.07(-5.85%)
At close: 4:00 PM EDT
€1.06
-€0.07(-5.85%)
Day’s Range― - ―
52-Week Range€0.86 - €2.35
Previous CloseN/A
Volume3.00K
Average Volume (3M)7.78K
Market Cap
€400.98M
Enterprise Value€506.12
Total Cash (Recent Filing)€100.05M
Total Debt (Recent Filing)€87.99M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding339,110,400
10 Day Avg. Volume10,159
30 Day Avg. Volume7,779
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.79Price Target Upside729.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€3.89M
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressFDA clearance and RMAT designation reduce regulatory uncertainty for OCU410 and support a registrational path. Alongside late-stage programs and defined filing targets, this creates multiple opportunities for future product approvals.
Pipeline And Manufacturing ReadinessProgress across three late-stage ophthalmic programs diversifies clinical catalysts and improves development execution. Completed enrollment and PPQ manufacturing batches can shorten the path from positive data to regulatory submission and potential commercialization.
International Licensing PotentialThe MENA agreement provides a framework for regional commercialization while preserving manufacturing participation and royalty economics. It also validates external interest in OCU400 and offers a partnership model that could expand access without requiring all market infrastructure internally.
Bears Say
Negative Equity And Rising DebtNegative equity and sharply higher debt weaken financial flexibility and increase refinancing risk. The capital structure may constrain strategic options and leave the company more dependent on equity issuance, partnerships, or other financing to sustain development.
Persistent Cash BurnOcugen is not self-funding and must continue converting financing or partnership opportunities into operating resources. Sustained cash outflows could require further capital before commercial revenues arrive, making execution and access to funding critical to pipeline continuity.
Unproven Profitability And Dilution RiskRevenue remains small relative to research and development needs, and the company has not demonstrated scalable profitability. Continued operating losses and potential use of warrants, share authorization, or other financing could dilute investors before products generate meaningful recurring revenue.
Ocugen News
2H51 FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was €0.86 and its highest was €2.35 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is €400.98M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Nov 10, 2026 which is in 73 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Aug 06, 2026. The company reported -€0.06 earnings per share for the quarter, missing the consensus estimate of -€0.046 by -€0.015.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 339,110,400 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -€0.06 in its last earnings report, missing expectations of -€0.046. Following the earnings report the stock price went up 0.709%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in DE:2H51
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.79 (729.49% Upside)
€8.79 (729.49% Upside)
Blogger Sentiment
Bullish
DE:2H51 Sentiment 80%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth €22.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
131.75%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
2H51 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.View all DE:2H51 earnings summaries2H51 Stock 12 Month Forecast
Average Price Target
€8.79
▲(729.49% Upside)